Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer
VIEWPOINTS

PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer

In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the enrolment of the final patient in the (ECLIPSE) trial for SHIELD blood test to treat Colorectal Cancer Shots: The company has reported the patient enrolment in the (ECLIPSE) trial to evaluate SHIELD blood test in 12750 patients aged 45-84yr. with colorectal…
March 9, 2022

Read more

Viewpoints_Kathryn Lang
VIEWPOINTS

PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on the Data of Guardant360 Liquid Biopsy Test for the Treatment of Advanced Non-Small Cell Lung Cancer

In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the data from the VALUE study of Guardant360 liquid biopsy test for NSCLC Shots: The VALUE study evaluates the clinical outcomes & utility of liquid biopsy vs tissue biopsy testing in patients with NSCLC across six Canadian centers In an initial diagnosis, patients treated…
November 29, 2021

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]